Precision Neurology: How Biomarkers Are Redefining Clinical Trial Design

Key Takeaways

• Biomarkers are reshaping neurological clinical trial design by enabling biologically informed patient selection, improving cohort homogeneity, and increasing the likelihood of detecting therapeutic effects.

• Imaging and fluid biomarkers provide complementary tools for measuring neurodegenerative disease biology, helping researchers monitor disease progression and evaluate therapeutic response. 

• Biomarker-driven precision medicine approaches are allowing researchers to identify biologically distinct patient subgroups within diseases such as Parkinson’s disease and Alzheimer’s disease.

• Large collaborative initiatives are accelerating biomarker discovery and validation, enabling researchers to collect standardized datasets and translate promising discoveries into clinical research tools.

• Future progress in neurodegenerative drug development will depend on biomarkers that can reliably track disease progression, identify disease subtypes, and measure biological responses to therapy.

Neurodegenerative diseases represent one of the most persistent and complex challenges in modern medicine. Disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD) collectively affect tens of millions of people worldwide and impose growing social and economic burdens as populations age. Despite decades of research and thousands of clinical trials, therapeutic progress has been uneven, and in many cases limited. Disease-modifying treatments remain rare, and they remain entirely elusive for several major neurodegenerative conditions.

Part of the difficulty lies in the biology of these diseases themselves. Neurodegenerative disorders often develop over many years or even decades before symptoms become clinically apparent. By the time cognitive decline, motor dysfunction, or behavioral changes bring patients to medical attention, extensive and often irreversible neuronal damage has already occurred. This long and poorly understood preclinical phase complicates both diagnosis and therapeutic intervention. Drug development programs must contend not only with complex and heterogeneous disease mechanisms but also with the challenge of identifying the right patients at the right stage of disease.

Clinical trials in neurology have historically relied heavily on functional and cognitive assessments as primary endpoints. These measures capture changes in symptoms or daily functioning, but they often provide only indirect insight into the underlying biological processes driving disease progression. As a result, demonstrating whether an investigational therapy is modifying disease biology or merely affecting symptoms can be difficult. This disconnect between clinical measures and underlying pathology has contributed to the high failure rates observed across many neurodegenerative drug development programs.

Another persistent challenge has been the difficulty of aligning mechanistic understanding of disease with clinical trial design. Therapeutic candidates are typically developed to target specific molecular pathways or pathological processes, but clinical endpoints frequently measure outcomes that may change only slowly or variably across patient populations. When the biological effect of a therapy cannot be clearly linked to measurable clinical outcomes, evaluating efficacy becomes far more difficult. This misalignment between mechanism, measurement, and clinical outcome has proven to be a central obstacle to therapeutic progress in neurodegenerative disease.

These limitations have led many researchers and drug developers to reassess how neurological diseases are studied and how clinical trials are designed. A growing consensus has emerged that improving the measurement of disease biology is essential for advancing the field. If researchers can more precisely identify disease processes, track their progression, and determine whether therapies are engaging the intended targets, the likelihood of successfully developing disease-modifying treatments may increase substantially. In this context, biomarkers have begun to emerge as one of the most promising tools for transforming the way neurological diseases are studied and treated.

The difficulty of measuring disease biology has been one of the defining challenges in neurological drug development. Many neurodegenerative disorders progress slowly and variably across patients, making it difficult for clinical trials to determine whether an investigational therapy is altering the underlying disease process within the timeframe of a study. As such, even well-designed trials may struggle to detect meaningful therapeutic effects.

Neurological trials have typically relied on clinical rating scales, cognitive tests, or functional assessments as primary endpoints. While these measures capture important aspects of patient experience, they provide only indirect insight into the biological mechanisms driving disease. Changes in these outcomes often emerge gradually and vary widely across patients, which can obscure the biological impact of a therapy and complicate interpretation of trial results.

These limitations have led to growing recognition that a central challenge in neurological drug development is the difficulty of measuring the disease itself. Without reliable ways to identify patients with specific biological pathologies, track disease progression, or detect biological responses to treatment, therapies that influence disease biology may still fail to demonstrate clear benefits in clinical trials. Biomarkers offer an opportunity to address this gap by providing measurable indicators of disease biology.

Biomarkers have attracted increasing attention as tools for improving clinical trial design. By helping researchers identify more homogeneous study populations, biomarkers can reduce variability within trial cohorts and strengthen statistical power. They may also allow investigators to link therapeutic mechanisms to measurable biological outcomes, strengthening the connection between experimental therapies and the endpoints used to evaluate them.

The importance of this alignment has become increasingly clear as researchers examine the causes of past trial failures. When biological mechanisms, biomarkers, and clinical endpoints do not align, even carefully designed studies may produce results that are difficult to interpret. Establishing clearer connections among these elements is now widely viewed as essential for advancing therapeutic development in neurodegenerative diseases.

As the limitations of traditional clinical endpoints became increasingly apparent, researchers began searching for tools that could more directly capture the biological processes underlying neurological disease. Biomarkers emerged as one of the most promising solutions to this measurement challenge. In the context of biomedical research, biomarkers are defined as measurable indicators of biological processes, pathogenic processes, or responses to therapeutic interventions. By providing quantifiable insights into disease biology, biomarkers can help bridge the gap between molecular mechanisms and clinical outcomes.

The concept has proven particularly valuable in neurological research, where many diseases unfold gradually and involve complex interactions among genetic, molecular, and cellular processes. Biomarkers offer a way to detect and monitor these processes in living patients, often long before clinical symptoms become pronounced. This capability has important implications not only for diagnosis but also for disease staging, patient stratification, and evaluation of therapeutic response.

In practice, neurological biomarkers are typically grouped into several major categories. Genetic biomarkers capture inherited or acquired genetic variations associated with disease risk or progression. Imaging biomarkers rely on neuroimaging technologies to visualize structural or functional changes in the brain. Fluid biomarkers measure disease-associated molecules in biological samples such as cerebrospinal fluid (CSF) or blood. Each of these approaches illuminates different aspects of disease biology, and many research programs increasingly integrate multiple biomarker types to build a more comprehensive picture of disease mechanisms.

These tools have begun to play an expanding role in clinical trials. Biomarkers can help identify patients who are most likely to have the specific biological pathology targeted by a therapy, allowing investigators to enrich trial populations with appropriate participants. They may also provide prognostic information about disease progression, enabling better stratification of patients across treatment arms. In addition, biomarkers can be used to monitor pharmacodynamic responses, offering early evidence that a therapy is engaging its intended biological target. In some cases, biomarkers may also support safety monitoring by detecting biological changes associated with adverse effects.

The increasing integration of biomarkers into neurological research reflects a broader shift in how the field approaches disease investigation and therapeutic development. Rather than relying solely on clinical symptoms to guide research and trial design, investigators are increasingly turning to biological measurements that provide a more direct view of disease processes. This transition has laid the foundation for a new generation of clinical trials designed not only to test therapeutic hypotheses but also to deepen understanding of the diseases themselves.

As biomarkers have become more widely available and better validated, they have begun to reshape how neurological clinical trials are designed and conducted. Their influence now spans multiple stages of drug development, from patient selection to the evaluation of therapeutic response. Rather than relying solely on clinical symptoms to define study populations and endpoints, many trials now incorporate biological measurements that more directly reflect disease mechanisms.

One of the most significant impacts of biomarkers has been in improving patient selection. Neurodegenerative diseases often encompass biologically diverse patient populations, even when individuals share similar clinical diagnoses. Biomarkers can help identify participants who exhibit specific pathological processes, enabling trials to focus on patients most likely to benefit from therapies targeting those mechanisms. This may involve selecting individuals with particular molecular signatures, imaging findings, or genetic variants associated with the disease under investigation. By supporting more precise diagnosis and enrollment criteria, biomarkers help create study populations that are more closely aligned with a therapy’s intended biological target.

Biomarker-based enrichment strategies can also improve trial efficiency. When study populations are more uniform with respect to underlying disease biology, variability within the cohort decreases, strengthening the ability of trials to detect treatment effects. Reduced variability may allow studies to reach interpretable results with fewer participants or shorter follow-up periods, making biomarker-guided trial design an increasingly common feature of neurological drug development.

Biomarkers also provide valuable insight into whether investigational therapies are producing their intended biological effects. Pharmacodynamic biomarkers can provide early evidence that a therapy is engaging its target or influencing relevant biological pathways. This information is especially valuable in early-phase trials, where confirmation of target engagement can guide dose selection, support decisions about continued development, or help interpret trial outcomes. In some cases, biomarkers may also reveal biological changes associated with potential safety concerns.

Beyond these operational roles, biomarkers increasingly inform broader therapeutic development strategies. By clarifying the biological mechanisms underlying disease progression and therapeutic response, they help researchers refine hypotheses about which pathways to target and which patient populations to prioritize. In this way, biomarkers contribute not only to the design of individual trials but also to the strategic direction of entire development programs.

Among the different classes of biomarkers now being integrated into neurological research, imaging biomarkers have played a particularly influential role. Advances in neuroimaging technologies have made it possible to visualize structural and functional changes in the brain with increasing precision, offering researchers new ways to study disease mechanisms in living patients. These tools allow investigators to observe patterns of neurodegeneration, regional brain atrophy, and other disease-associated changes that may unfold long before symptoms become severe.

In the context of neurodegenerative disease research, imaging biomarkers are widely used to examine how diseases affect specific neural circuits and brain regions. Structural neuroimaging techniques, including magnetic resonance imaging (MRI), can reveal patterns of tissue loss or morphological change associated with particular disorders. These observations help researchers better understand how disease progresses over time and how different patient populations may exhibit distinct patterns of neurodegeneration. As a result, imaging biomarkers have become important tools for studying disease mechanisms and monitoring progression across a range of neurological conditions.

Imaging biomarkers also play an expanding role in clinical research and diagnostic investigation. Structural neuroimaging approaches are being actively studied as potential diagnostic tools for conditions like PD, where identifying reliable biological indicators of disease remains an important research goal. Investigators continue to evaluate how patterns of structural brain changes detected through neuroimaging may help distinguish PD from other neurological disorders and support earlier detection of disease.¹

Beyond diagnosis, imaging biomarkers are increasingly incorporated into clinical trials as tools for tracking disease progression and evaluating therapeutic effects. By providing objective measurements of structural or functional changes in the brain, neuroimaging can complement clinical assessments that focus on symptoms or functional outcomes. This combination of biological and clinical measurements allows researchers to build a more complete picture of how disease evolves and how investigational therapies may influence its course.

While imaging biomarkers provide valuable insight into structural and functional changes in the brain, fluid biomarkers offer a complementary approach that can be more easily scaled across large patient populations. By measuring disease-associated molecules in biological fluids, such as blood or CSF, researchers can obtain information about underlying disease processes without relying exclusively on complex imaging technologies. This accessibility has made fluid biomarkers an increasingly attractive tool for both clinical research and routine monitoring of neurological disease.

Fluid biomarkers encompass a broad range of biological signals, including proteins, nucleic acids, metabolites, and other molecular indicators associated with pathological processes in the nervous system. Because many of these molecules originate from cells affected by disease, their presence or concentration in biological fluids can reflect ongoing changes in brain biology. As a result, fluid biomarkers are being actively investigated as potential diagnostic indicators, tools for tracking disease progression, and measures of therapeutic response in neurodegenerative disorders.²

One important area of investigation involves blood-based biomarkers, which offer the possibility of monitoring neurological disease using relatively simple and minimally invasive sampling methods. Blood-based assays are particularly attractive for large clinical trials and longitudinal studies, where repeated sampling may be required to track disease progression or therapeutic effects. Advances in molecular detection technologies have expanded the range of analytes that can be measured reliably in blood, enabling researchers to explore a growing set of candidate biomarkers linked to neurodegenerative pathology.

These approaches are being actively explored within major collaborative research initiatives. For example, the Parkinson’s Disease Biomarkers Program (PDBP), launched by the National Institute of Neurological Disorders and Stroke (NINDS), has investigated a range of molecular signals, including RNA-based biomarkers detectable in blood samples. Such studies aim to identify biological signatures associated with PD that could eventually support earlier diagnosis, improved disease monitoring, or more effective patient stratification in clinical trials.³

The continued expansion of fluid biomarker research reflects a broader effort to make biological measurements more accessible within neurological studies. Compared with many imaging approaches, fluid biomarkers have the potential to be deployed more widely across clinical settings and patient populations. If validated successfully, these tools could help bring biological measurement closer to routine clinical practice while also supporting more efficient and informative clinical trials.

As the understanding of neurodegenerative disease biology has deepened, it has become increasingly clear that many neurological disorders encompass a wide range of underlying biological processes. Patients who share the same clinical diagnosis may nonetheless exhibit important differences in disease mechanisms, progression patterns, and responses to therapy. This heterogeneity has complicated drug development efforts, as treatments designed to target a specific biological pathway may only benefit a subset of patients within a clinically defined population.

Biomarkers offer a potential path toward addressing this challenge by enabling more precise characterization of disease biology. Rather than treating neurological diseases as single, uniform entities, biomarker-driven research seeks to identify biological subgroups within broader diagnostic categories. In PD, for example, investigators have explored a range of molecular, genetic, and biochemical indicators that may distinguish distinct patient subpopulations and clarify differences in disease mechanisms. Identifying such subgroups could improve understanding of disease heterogeneity and help guide more targeted therapeutic strategies.⁴

These efforts align with broader movements toward precision medicine, in which treatments are tailored to the biological characteristics of individual patients or patient subgroups. In the context of neurological research, biomarkers may help determine which patients are most likely to benefit from therapies that target specific molecular pathways. By enabling more refined patient stratification, biomarker-based approaches may improve the efficiency of clinical trials and increase the likelihood of detecting meaningful therapeutic effects.

Biomarkers are also being explored as tools for disease staging. Emerging frameworks for PD incorporate biomarker data alongside clinical assessments to categorize patients according to underlying disease biology. Such frameworks aim to move beyond symptom-based classification systems by incorporating biological indicators that reflect the progression of pathological processes. These approaches may help researchers identify earlier stages of disease, track disease evolution over time, and design clinical trials that enroll patients at the most appropriate stage for a given therapeutic intervention.⁵

As interest in biomarkers has grown, large collaborative research initiatives have emerged to accelerate their discovery, validation, and integration into clinical research. Developing reliable biomarkers for complex neurological diseases often requires extensive datasets, standardized methods, and access to well-characterized patient populations. These requirements have encouraged the formation of coordinated programs that bring together academic researchers, clinical investigators, industry partners, and government agencies to pursue biomarker research on a broader scale.

One prominent example is the PDBP, which was established to identify and validate biomarkers associated with PD to improve understanding of disease mechanisms and supporting more effective therapeutic development.⁶ By assembling clinical data and biological samples from large patient cohorts, the initiative provides a shared resource that researchers can use to investigate candidate biomarkers across multiple studies.

Such programs are designed not only to generate new biomarker discoveries but also to evaluate how those biomarkers might be used in clinical research. Studies conducted within the program examine a range of potential applications, including improving diagnostic accuracy, identifying prognostic indicators of disease progression, and informing clinical trial design. By linking biological data with longitudinal clinical observations, investigators aim to determine which biomarkers reliably reflect disease processes and which may serve as useful tools in therapeutic development.⁶

The scale of these initiatives reflects the recognition that biomarker discovery in neurodegenerative disease often requires coordinated efforts across institutions and disciplines. Large biomarker programs supported by organizations such as NINDS have enabled extensive discovery efforts by providing shared infrastructure for sample collection, data analysis, and collaborative research. Through these efforts, investigators can pursue biomarker development with the breadth and statistical power necessary to identify signals that might otherwise remain undetected in smaller studies.⁷

Collaborative programs also play an important role in establishing common standards for biomarker research. Standardized protocols for sample collection, data management, and analytical methods can improve the comparability of results across studies and help accelerate the translation of promising biomarkers from discovery into clinical application. As these initiatives continue to expand, they are expected to remain central to efforts aimed at transforming biomarker research into practical tools for neurological diagnosis and drug development.

Despite significant progress over the past two decades, important gaps remain in the biomarker landscape for neurodegenerative diseases. Many conditions still lack biomarkers capable of supporting the full range of needs in clinical research. While some tools have proven useful for diagnosis or limited disease monitoring, there remains a need for biomarkers that can reliably distinguish disease subtypes, track progression over time, and measure biological response to therapy across diverse patient populations.

Although numerous candidate PD biomarkers have been identified, the field continues to seek validated indicators that can support early diagnosis, predict disease trajectory, and enable more effective clinical trial design. In particular, the lack of robust progression and response biomarkers limits the ability to evaluate therapeutic impact with confidence. The need for such tools has been described as urgent within PD research, underscoring broader challenges across neurodegenerative diseases.

A critical unmet need lies in distinguishing biologically meaningful subgroups within clinically defined diseases. Many neurodegenerative conditions encompass multiple underlying pathologies and disease mechanisms, which are not fully captured by current diagnostic frameworks. In PD research, investigators have emphasized the importance of identifying biomarkers that can differentiate among disease subtypes and clarify the biological drivers of disease in distinct patient populations.4 Such capabilities are essential for advancing more targeted therapeutic approaches.

Beyond subtype identification, there is a growing need for biomarkers that can track disease progression and provide clear, interpretable signals of therapeutic response. Without reliable measures of how disease biology changes over time — and how it responds to intervention — clinical trials may struggle to determine whether a therapy is having a meaningful effect.

In this sense, the “biomarker wish list” extends beyond the discovery of individual markers. What is needed are integrated tools that can characterize disease heterogeneity, monitor biological change, and detect treatment effects in a consistent and clinically meaningful way. Developing such biomarkers remains one of the most important challenges in neurological research.

The expanding role of biomarkers reflects a broader transformation in how neurological diseases are studied and how therapies are developed. As research increasingly shifts toward earlier intervention, biologically defined patient populations, and mechanism-driven therapeutics, the ability to measure disease biology with precision is becoming indispensable. Biomarkers are helping move the field beyond symptom-based descriptions of disease toward a more mechanistic understanding of neurodegeneration.

Looking ahead, the continued evolution of biomarker science will likely shape the next generation of neurological research. Advances in molecular profiling, imaging technologies, and fluid-based diagnostics are rapidly expanding the range of biological signals that can be measured in living patients. These capabilities may allow researchers to detect disease earlier, monitor biological changes more accurately, and evaluate therapeutic effects with greater confidence. As a result, biomarkers are expected to play an increasingly important role in accelerating drug development targeting aging-related and neurodegenerative biology.

Realizing this potential, however, will require sustained collaboration across academia, industry, and regulatory agencies. Large-scale data sharing, standardized analytical methods, and coordinated validation efforts will be essential for ensuring that promising biomarker discoveries can be translated into reliable tools for clinical research and clinical care. Building the infrastructure needed to support these efforts represents a critical step toward strengthening the foundations of neurological drug development.

The promise of biomarkers ultimately lies not only in the discovery of new measurements, but in the creation of a research ecosystem capable of integrating biological insight with therapeutic innovation. Continued investment in biomarker discovery, validation, and implementation will therefore play a central role in determining whether emerging scientific advances can be translated into effective treatments for neurodegenerative disease.

1. Torres-Parga, Alejandra, et al. “Diagnostic performance of T1-Weighted MRI gray matter biomarkers in Parkinson’s disease: A systematic review and meta-analysis.” Parkinsonism & Related Disorders. 140: 108009 (2025).

2. Selvam, Satish and Velpandi Ayyavoo. “Biomarkers in neurodegenerative diseases: a broad overview.” Explor. Neuroprot. Ther. 4: 119–147 (2024).

3. Santiago, Jose A, Virginie Bottero, and Judith A Potashkin. “Evaluation of RNA Blood Biomarkers in the Parkinson’s Disease Biomarkers Program.” Front. Aging Neurosci. 10: 157 (2018).

4. Chen-Plotkin, Alice, et al. “Finding useful biomarkers for Parkinson’s disease.” Science Translational Medicine. 10: 454 (2018).

5. Russo, Marco J, and Un Jung Kang. “New Diagnostic and Staging Framework Applied to Established PD in the BioFIND Cohort.” Res. Sq. 28: rs.3.rs-6003205 (2025).

6. Gwinn, Katrina, et al. “Parkinson’s disease biomarkers: perspective from the NINDS Parkinson’s Disease Biomarkers Program.” Biomark. Med. 11: 451–473 (2017).

7. Rosenthal, Liana S, et al. “The NINDS Parkinson’s disease biomarkers program.” Mov. Disord. 31: 915–923 (2016).